LifeCycle Pharma Announces Positive Top-Line Results Of Phase II Clinical Trial Of LCP-Tacro In Stable Kidney Transplant Patients
LifeCycle Pharma A/S (OMX: LCP), announced positive to top-line results from a completed Phase II clinical trial for LCP-Tacro in stable kidney transplant patients.
More: continued here
Filed under: Transplants on March 15th, 2008